Circulating plasma microRNA profiling in patients with polymyositis/dermatomyositis before and after treatment: miRNA may be associated with polymyositis/dermatomyositis

• Published in: Inflammation and Regeneration Vol. 38; no. 1; p. 1
• Main Authors: Hirai, Takuya, Ikeda, Keigo, Tsushima, Hiroshi, Fujishiro, Maki, Hayakawa, Kunihiro, Yoshida, Yuko, Morimoto, Shinji, Yamaji, Ken, Takasaki, Yoshinari, Takamori, Kenji, Tamura, Naoto, Sekigawa, Iwao
• Format: Journal Article
• Language: English
• Published: England BioMed Central 2018; BMC
• Subjects: Autoimmune diseases; Biomarkers; Dermatomyositis; Disease; Enzymes; Lupus; MicroRNA; MicroRNAs; Pathogenesis; Patients; Plasma; Polymyositis; Statistical analysis; Tumors; Womens health; United States > US; Japan; Plasma; Polymyositis; MicroRNA; Dermatomyositis
• ISSN: 1880-9693; 1880-8190
• DOI: 10.1186/s41232-017-0058-1

MicroRNAs (miRNAs) are involved in the regulation of key biological processes and have been implicated in various diseases, including autoimmune disorders. The pathogenesis of polymyositis (PM) and dermatomyositis (DM) is considered to be mediated by autoimmune reactions. To determine miRNA role in the development and progression of PM and DM, we performed plasma miRNA profiling in PM/DM patients before and after treatment. Total RNA was isolated from plasma of 10 patients before and after treatment with prednisolone, or, in case of prednisolone resistance or complications, with the combination of calcineurin inhibitors (cyclosporine or tacrolims) and/or pulse intravenous cyclophosphamide. The expression of miRNAs was determined using miRNA microarray and validated by qRT-PCR. More differentially expressed miRNAs were found in plasma of DM patients compared to PM patients before and after treatment, and their profiles were different. Among the differentially expressed plasma miRNA identified by microarray, the levels of hsa-miR-4442 were confirmed by qRT-PCR to be significantly decreased by treatment. In addition, plasma hsa-miR-4442 content in active PM/DM significantly exceeded that in other active autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, as well as in healthy individuals. The level of plasma hsa-miR-4442 was positively correlated with Skeletal Disease Activity in MITAX (Myositis Intention to Treat Activity Index). This is the first report describing plasma miRNA expression profiles in PM/DM patients. The present data suggest that plasma levels of miRNAs may be associated with polymyositis/dermatomyositis and hsa-miR-4442 could be used as a biomarker for PM/DM diagnosis and/or disease activity.